Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brett Ley

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
The European Respiratory Journal|October 30, 2020
Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitisAyodeji Adegunsoye, Julie Morisset, Chad A Newton, et al.
Chest|June 11, 2019
Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary FibrosisGabrielle Y Liu, Iazsmin Bauer Ventura, Natalia Achtar-Zadeh, et al.
Radiology|June 14, 2014
Idiopathic pulmonary fibrosis: CT and risk of deathBrett Ley, Brett M Elicker, Thomas E Hartman, et al.
Annals of Internal Medicine|May 16, 2012
A multidimensional index and staging system for idiopathic pulmonary fibrosisBrett Ley, Christopher J Ryerson, Eric Vittinghoff, et al.
Thorax|March 20, 2012
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosisLuca Richeldi, Christopher J Ryerson, Joyce S Lee, et al.
Chest|October 12, 2013
Predicting survival across chronic interstitial lung disease: the ILD-GAP modelChristopher J Ryerson, Eric Vittinghoff, Brett Ley, et al.
The Lancet. Respiratory Medicine|June 27, 2017
The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control studyBrett Ley, Chad A Newton, Isabel Arnould, et al.
The European Respiratory Journal|January 13, 2019
Telomere length and genetic variant associations with interstitial lung disease progression and survivalChad A Newton, Justin M Oldham, Brett Ley, et al.
Chest|November 7, 2016
Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity PneumonitisJulie Morisset, Kerri A Johannson, Eric Vittinghoff, et al.
The Lancet. Respiratory Medicine|August 4, 2018
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trialsMargaret Neighbors, Christopher R Cabanski, Thirumalai R Ramalingam, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
The European Respiratory Journal|October 30, 2020
Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitisAyodeji Adegunsoye, Julie Morisset, Chad A Newton, et al.
Chest|June 11, 2019
Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary FibrosisGabrielle Y Liu, Iazsmin Bauer Ventura, Natalia Achtar-Zadeh, et al.
Radiology|June 14, 2014
Idiopathic pulmonary fibrosis: CT and risk of deathBrett Ley, Brett M Elicker, Thomas E Hartman, et al.
Annals of Internal Medicine|May 16, 2012
A multidimensional index and staging system for idiopathic pulmonary fibrosisBrett Ley, Christopher J Ryerson, Eric Vittinghoff, et al.
Thorax|March 20, 2012
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosisLuca Richeldi, Christopher J Ryerson, Joyce S Lee, et al.
Chest|October 12, 2013
Predicting survival across chronic interstitial lung disease: the ILD-GAP modelChristopher J Ryerson, Eric Vittinghoff, Brett Ley, et al.
The Lancet. Respiratory Medicine|June 27, 2017
The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control studyBrett Ley, Chad A Newton, Isabel Arnould, et al.
The European Respiratory Journal|January 13, 2019
Telomere length and genetic variant associations with interstitial lung disease progression and survivalChad A Newton, Justin M Oldham, Brett Ley, et al.
Chest|November 7, 2016
Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity PneumonitisJulie Morisset, Kerri A Johannson, Eric Vittinghoff, et al.
The Lancet. Respiratory Medicine|August 4, 2018
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trialsMargaret Neighbors, Christopher R Cabanski, Thirumalai R Ramalingam, et al.
Pageof 6